

Charity number: 1123760
Company number: 6078396
(England and Wales)

British Society for Histocompatibility and Immunogenetics
Report of the Trustees and Unaudited Financial Statements
For the year ended 31 December 2020

British Society for Histocompatibility and Immunogenetics
Contents Page
For the year ended 31 December 2020

Report of the Trustees	1 to 3
Independent Examiner's Report to the Trustees	4
Statement of Financial Activities	5
Statement of Financial Position	6
Notes to the Financial Statements	7 to 12
Detailed Statement of Financial Activities	13 to 14

British Society for Histocompatibility and Immunogenetics
Report of the Trustees
For the year ended 31 December 2020

The Trustees, who are also directors for the purposes of company law, have pleasure in presenting their report and the financial statements for the charitable company for the year ended 31 December 2020. The Trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

The objects of the Society, as stated in its Memorandum of Association, are;

To promote and protect health for the public benefit in particular by:

(a) developing and maintaining good practice in Histocompatibility and Immunogenetics by ensuring the highest professional standards of competence;

(b) encouraging the advancement of scientific research and knowledge and of its application in all aspects of Histocompatibility and Immunogenetics and disseminating the useful results thereof.

The main activities of the society that contribute to the achievement of the objectives are;

Annual Conference

BSHI Annual Conference for 2020 was postponed due to the COVID-19 pandemic. It was held jointly with the European Federation of Immunogenetics (EFI) in April 2021 as a virtual event. The meeting provided an educational programme of lectures and seminars. Plenary lectures were provided by world experts in the field of Histocompatibility and Immunogenetics. Sessions were run allowing BSHI Members to present short papers and posters of their current research to a worldwide audience of experts.

Two awards sessions were held. The first for best abstract submitted and a session dedicated to presentations from young scientists within the society.

Objectives and aims

The trustees have considered the Charity Commission's guidance on public benefit, including the guidance 'public benefit: running a charity (PB2)'.

ACHIEVEMENTS AND PERFORMANCE

Diploma and other training courses

A successful series of one and two day training courses were held to support Trainee Clinical Scientists, Biomedical Scientists and those undertaking higher qualifications. Graduating diplomats received their awards at the Annual Conference.

BSHI ran a higher training meeting for members considering taking the FRC Path examinations.

BSHI also administers a CPD scheme for the membership.

British Society for Histocompatibility and Immunogenetics
Report of the Trustees Continued
For the year ended 31 December 2020

ACHIEVEMENTS AND PERFORMANCE CONTINUED

Bursaries and Grants

BSHI supplied bursaries to its members to attend scientific and educational meetings. These included the European Federation of Immunogenetics and British Society for Histocompatibility and Immunogenetics meetings.

The society also awarded the Julia Bodmer Travel Award, which allows a junior member of the society the opportunity to visit another laboratory to bring back some research ideas or new technology to their own laboratory. The recipient of the award presents their findings at the BSHI annual conference.

Representation to other professional bodies

The BSHI has nominated representatives to a number of other professional organisations and these representatives link to the BSHI Committee through the Professional Advisory Group. Elected members of BPAG are responsible for co-ordinating BSHI input to official working groups and documents.

BSHI is represented at the Association of Clinical Scientists, Clinical Pathology Accreditation UK Ltd, the Federation of Healthcare Science, the National External Quality Assurance Advisory Panel for Immunology, and the Royal College of Pathologists and NHSBT-ODT advisor groups.

Establishment and maintenance of appropriate standards within H & I is addressed through the BPAG. BPAG will interact with other professional organisations e.g. European Federation for Immunogenetics, British Transplantation Society as required and set up Standards Working Groups to address specific topics.

Online Virtual Conference Facility

BSHI provides virtual conference infrastructure via Cisco Webex and Zoom meeting to the memberships, enabling remote conferencing and education to take place and at the same time reducing waste and carbon impact.

Online Scientific Journals

BSHI continues to supply access to scientific literature that members do not readily have access to.

Online CPD Scheme

BSHI provides and manages online Continuing Professional Development (CPD) schemes for its members via CPDMe.

Publications

BSHI publishes a quarterly newsletter which is sent to all of the memberships. This contains reports from meetings, CPD journal based learning exercises and updates on developments within the society.

FINANCIAL REVIEW

Reserves

The overall reserves of the charity have decreased to £105,936 due to COVID-19 restrictions. However, the reserves are still leaving the charity in a strong position to continue to pursue its objectives for the foreseeable future.

Going concern

The trustees are confident that BSHI will be able to continue and pursue its objectives for the foreseeable future.

British Society for Histocompatibility and Immunogenetics
Report of the Trustees Continued
For the year ended 31 December 2020

REFERENCE AND ADMINISTRATIVE INFORMATION

Name of Charity	British Society for Histocompatibility and Immunogenetics
Charity registration number	1123760
Company registration number	6078396
Principal address	C/O Executive Business Support Ltd City Wharf Davidson Road Lichfield Staffs WS14 9DZ

Trustees

The trustees and officer serving during the year and since the year end were as follows:

Sarah Peacock
Richard Battle
Mian Chen
Marie Hampson
Helena Lee
Carla Rosser
Andrea Harmer Resigned Dec 2020
Paul Dunn Resigned Dec 2020
Deborah Sage
Natalia Diaz Burlinson
Franco Tavarozzi
Rachel Smith Appointed Dec 2020

Independent examiner

Marie Hartwell
VESEY Accounting Services Ltd
34 High Street
Sutton Coldfield
West Midlands
B72 1UP

Bankers

Barclays Bank Plc
Witham Business Centre
59 Newland Street
Witham
Essex
CM8 2AJ

Approved by the Board of Trustees and signed on its behalf by

Mian Chen.....  14 May 2021

British Society for Histocompatibility and Immunogenetics
Independent Examiners Report to the Trustees
For the year ended 31 December 2020

I report to the trustees on my examination of the accounts of the charitable company for the year ended 31 December 2020.

Responsibilities and basis of report

As the charity Trustees, who are also directors for the purposes of company law, are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiners qualified statement

I confirm that no other matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I confirm that there are no other matters to which your attention should be drawn to enable a proper understanding of the accounts to be reached.



Marie Hartwell
VESEY Accounting Services Ltd
34 High Street
Sutton Coldfield
West Midlands
B72 1UP
14 May 2021

British Society for Histocompatibility and Immunogenetics
Statement of Financial Activities (including Income and Expenditure Account)
For the year ended 31 December 2020

	Notes	Unrestricted funds £	2019 £
Income and endowments from:			
Charitable activities	2	35,271	69,788
Investments	3	656	869
Total		35,927	70,657
Expenditure on:			
Charitable activities	4/5	(71,643)	(68,828)
Total		(71,643)	(68,828)
Net Income/expenditure		(35,716)	1,829
Reconciliation of funds			
Total funds brought forward		141,652	139,823
Total funds carried forward		105,936	141,652

British Society for Histocompatibility and Immunogenetics
Statement of Financial Position
As at 31 December 2020

	Notes	2020 £	2019 £
Fixed assets			
Intangible assets	11	-	2,223
Tangible assets	12	68	91
		<u>68</u>	<u>2,314</u>
Current assets			
Debtors	13	15,085	27,742
Cash at bank and in hand		94,132	114,716
		<u>109,217</u>	<u>142,458</u>
Creditors: amounts falling due within one year	14	(3,349)	(3,120)
Net current assets		<u>105,868</u>	<u>139,338</u>
Total assets less current liabilities		<u>105,936</u>	<u>141,652</u>
Net assets		<u>105,936</u>	<u>141,652</u>
The funds of the charity			
Unrestricted income funds	15	105,936	141,652
Total funds		<u>105,936</u>	<u>141,652</u>

For the year ended 31 December 2020 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476,

The trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the Board and signed on its behalf by:


Mian Chen
Trustee

14 May 2021

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements
For the year ended 31 December 2020

1. Accounting Policies

Basis of accounting

The financial statements have been prepared under the historical cost convention, except for investments which are included at market value and the revaluation of certain fixed assets and in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), and the Companies Act 2006.

British Society for Histocompatibility and Immunogenetics meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

Going concern

Since 31 December 2019, in common with many other organisations, the outbreak of COVID-19 and the measures being taken to control its spread, have had a detrimental impact on the financial year ending 31st December 2020. Specifically, Individual member subscriptions are just over a 3rd of the previous year and due to lockdown and social distancing measures no Workshop Training was able to take place. At the date of reporting the accounts, the duration and impact of the COVID-19 pandemic, as well as the effectiveness of government lockdown measures and the roll out of the vaccination programmes remains unclear at this time. It is not possible to reliably estimate the duration and severity of these consequences, as well as their impact on the financial position and results of the organisation for future periods. However, the trustees are confident that BSHI will be able to continue and pursue its objectives for the immediate foreseeable future.

Incoming resources

All incoming resources are included in the statement of financial activities when the Charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:

Income from investments is included in the year in which it is receivable.

Resources expended

Liabilities are recognised as resources expended when there is a legal or constructive obligation committing the Charity to the expenditure:

Tangible fixed assets

Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:

Plant and machinery	25% Reducing balance
Computer equipment	25% Reducing balance
Motor vehicles	25% Reducing balance
Fixtures and fittings	25% Reducing balance

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2020

2. Income from charitable activities

	2020 £	2019 £
Unrestricted funds		
<i>Charitable activities</i>		
Advertising	7,020	15,825
Subscriptions	11,815	32,620
Conference	(2,419)	1,205
Qualifications	18,755	19,218
	<u>35,171</u>	<u>68,868</u>
<i>Other member activities</i>		
Other member activities	100	920
	<u>35,271</u>	<u>69,788</u>

3. Investment income

	2020 £	2019 £
Unrestricted funds		
Bank interest receivable	656	869
	<u>656</u>	<u>869</u>

4. Costs of charitable activities by fund type

	2020 £	2019 £
Unrestricted funds		
Charitable activities	33,492	35,976
Support costs	38,151	32,852
	<u>71,643</u>	<u>68,828</u>

5. Costs of charitable activities by activity type

	Activities undertaken directly £	Support costs £	2020 £	2019 £
Support costs				
Charitable activities	33,492	38,151	71,643	68,828

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2020

6. Analysis of support costs

	2020	2019
	£	£
Charitable activities		
Management	2,052	9,213
Finance	541	1,466
Computer costs	2,379	3,613
Depreciation & amortisation	2,246	2,253
EBS Admin charges	18,165	11,433
International Journal of Immunogenetics	5,414	-
Print, post & stationery	39	116
Subscriptions	1,120	794
Telephone	1,133	1,311
Governance costs	5,062	2,653
	<u>38,151</u>	<u>32,852</u>

7. Net income/(expenditure) for the year

This is stated after charging/(crediting):

	2020	2019
	£	£
Depreciation of owned fixed assets	23	30
Amortisation of intangible fixed assets	2,223	2,223
Accountancy fees	1,200	1,200

8. Staff costs

No staff costs or emoluments were paid in the year.

	2020	2019
Employees	0	0
	<u>0</u>	<u>0</u>

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2020

10. Comparative for the Statement of Financial Activities

The comparative year values on the Statement of Financial Activities are for unrestricted funds.

11. Intangible fixed assets

	Intangible asset 1
Cost or valuation	£
At 01 January 2020	6,668
At 31 December 2020	<u>6,668</u>
Amortisation	
At 01 January 2020	4,445
Charge for year	2,223
At 31 December 2020	<u>6,668</u>
Net book values	
At 31 December 2020	<u>-</u>
At 31 December 2019	<u>2,223</u>

12. Tangible fixed assets

	Plant and machinery
Cost or valuation	£
At 01 January 2020	380
At 31 December 2020	<u>380</u>
Depreciation	
At 01 January 2020	289
Charge for year	23
At 31 December 2020	<u>312</u>
Net book values	
At 31 December 2020	<u>68</u>
At 31 December 2019	<u>91</u>

Tangible fixed assets

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2020

13. Debtors

	2020 £	2019 £
Amounts due within one year:		
Trade debtors	3,472	10,735
Prepayments and accrued income	11,613	17,007
	<u>15,085</u>	<u>27,742</u>

14. Creditors: amounts falling due within one year

	2020 £	2019 £
Trade creditors	3,349	3,120
	<u>3,349</u>	<u>3,120</u>

15. Movement in funds

Unrestricted Funds

	Balance at 01/01/2020 £	Incoming resources £	Outgoing resources £	Balance at 31/12/2020 £
General	141,652	35,927	(71,643)	105,936
	<u>141,652</u>	<u>35,927</u>	<u>(71,643)</u>	<u>105,936</u>

Unrestricted Funds - Previous year

	Balance at 01/01/2019 £	Incoming resources £	Outgoing resources £	Balance at 31/12/2019 £
General	139,823	70,657	(68,828)	141,652
	<u>139,823</u>	<u>70,657</u>	<u>(68,828)</u>	<u>141,652</u>

Purpose of unrestricted Funds

General

Unrestricted funds are funds that can only be used in accordance with the charitable objects and at the discretion of the trustees.

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2020

16. Analysis of net assets between funds

	Intangible fixed assets	Tangible fixed assets	Net current assets / (liabilities)	Net Assets
	£	£	£	£
Unrestricted funds				
General	-	68	105,868	105,936
	-	68	105,868	105,936

Previous year

	Intangible fixed assets	Tangible fixed assets	Net current assets / (liabilities)	Net Assets
	£	£	£	£
Unrestricted funds				
General	2,223	91	139,338	141,652
	2,223	91	139,338	141,652

17. Company limited by guarantee

British Society for Histocompatibility and Immunogenetics is a company limited by guarantee and accordingly does not have a share capital.

British Society for Histocompatibility and Immunogenetics
Detailed Statement of Financial Activities
For the year ended 31 December 2020

	2020 £	2019 £
INCOME AND ENDOWMENT		
Charitable activities		
Advertising	7,020	15,825
Subscriptions	11,815	32,620
Conference	(2,419)	1,205
Qualifications	18,755	19,218
Other member activities	100	920
	35,271	69,788
Investments		
Bank interest receivable	656	869
	656	869
Total incoming resources	35,927	70,657
EXPENDITURE		
Charitable activities		
Cost of direct charitable activity	(33,492)	(35,976)
	(33,492)	(35,976)
SUPPORT COSTS		
Management		
Management	(2,052)	(9,213)
	(2,052)	(9,213)
Finance		
Finance	(541)	(1,466)
	(541)	(1,466)
Computer costs		
Computer costs	(2,379)	(3,613)
	(2,379)	(3,613)
Depreciation & amortisation		
Depreciation & amortisation	(2,246)	(2,253)
	(2,246)	(2,253)
EBS Admin charges		
EBS Admin charges	(18,165)	(11,433)
	(18,165)	(11,433)
International Journal of Immunogenetics		
International Journal of Immunogenetics	(5,414)	-
	(5,414)	-
Print, post & stationery		
Print, post & stationery	(39)	(116)
	(39)	(116)
Subscriptions		

British Society for Histocompatibility and Immunogenetics
Detailed Statement of Financial Activities Continued
For the year ended 31 December 2020

Subscriptions	(1,120)	(794)
	(1,120)	(794)
Telephone		
Telephone	(1,133)	(1,311)
	(1,133)	(1,311)
Governance costs		
Governance costs	(5,062)	(2,653)
	(5,062)	(2,653)
Total resources expended	(71,643)	(68,828)
Net Expenditure	(35,716)	1,829